Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer: Is it cost-effective?

Acta Oncologica

Volumn 39, Issue 1, 2000, Pages 33-39

  Norum, Jan ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUOROURACIL; METHOTREXATE; ONDANSETRON;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; COST BENEFIT ANALYSIS; DRUG EFFICACY; HUMAN; MORBIDITY; NORWAY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0034002168     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600430941     Document Type: Article

References (45)

1. Miller AB. Causes of breast cancer and high-risk groups. Incidence and demographics, radiation risk. In: Harris JR, Hellmann S, Henderson IC, Kinne DW, eds. Breast disease, Philadelphia: JB Lippincott Company, 1991: 119.
2. Wingo PA, Tong T, Bolden S. Cancer Statistics. 1995. CA Cancer J Clin 1995; 45: 8-30.
3. Parkin DM, Laara E, Muir CS. Estimate of world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
4. Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents. Volume 5. Lyon, France: International Agency for Research on Cancer, 1987.
5. Cory JF, Lønning PE. Systemic therapy in breast cancer: efficacy and cost utility. PharmacoEconom 1994; 5: 198-204.
6. Henderson CI. Adjuvant chemotherapy for breast cancer. N Engl J Med 1988; 318: 443-4.
7. The Norwegian Breast Cancer Group (NBCG). Breast cancer, diagnosis and treatment. The Norwegian Cancer Union, Oslo, 1998.
8. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer, progress and controversy. CA Cancer J Clin 1995; 45: 199-226.
9. Fisher B, Carbone P, Economou SG, et al. L-phenylalanin mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975; 292: 117-22.
10. Bonadonna G, Valagussa P, Zambetti M, et al. Milan adjuvant trials for stage I-II breast cancer. In: Salmon SE, ed. Adjuvant therapy of cancer. Orlando: Grune and Stratton, 1987: 211.
11. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339: 1-15.
12. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer. Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983; 1: 2-10.
13. Schumaker M, Baster G, Bojar H, et al. Randomised 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node positive breast cancer patients. J Clin Oncol 1994; 12: 2086-93.
14. Bonadonna G, Valagussa P, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer. The results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
15. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-94.
16. Levine M, Bramwell V, Pritchard K, Shepered L. CEF versus CMF in premenopausal women - recent update. Eur J Cancer 1998; 34 (Suppl 1): Abstract S35.
17. Galligioni E, Cetto G, Nascimben O, et al. High dose epirubicin and cyclophosphamide (EC) vs. cylophosphamide, methorexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomised trial. Eur J Cancer 1998; 34 (Suppl 1): P84.
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer. An overview of the randomised trials. Lancet 1998; 352: 930-42.
19. Bonadonna GI, Valagussa P, Tancini G, et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1986; 1: 45-9.
20. Buzdar AU, Kau SW, Smith TL, Hortobagi GN. Ten year results of FAC adjuvant chemotherapy trials in breast cancer. Am J Clin Oncol 1989; 12: 123-8.
21. Irvin RJ, Kuhn JG. Financial considerations in the use of adjuvant chemotherapy. In: Henderson IC, ed. Adjuvant therapy of breast cancer. [Location?]: Kluwer Academic Publishers, 1992; 207-22.
22. Luce BR, Elixhauser A. Standards for the socioeconomic evaluation of health care services. Berlin: Springer, 1990.
23. Trippoli S, Becagli Å, Messori A. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer. A lifetime cost-utility analysis based on a modified Q-TWIST method. Eur J Clin Pharmacol 1997; 53: 281-2.
24. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer. Meta-analysis of quality-adjusted survival. Lancet 1996; 347: 1066-71.
25. Rensing K, Stockhausen LV, Wallwiener D, Grischke EM, Bastert G. Assessment of changes in life quality of breast cancer patients under adjuvant CMF-chemotherapy by means of the EORTC QLQ-C30. Fur J Cancer 1998; 34 (Suppl 1): Abstract P108.
26. Norum J, Olsen JA, Wist EA. Lumpectomy or mastectomy? Is breast conserving surgery too expensive? Breast Cancer Res Treat 1997; 45: 7-14.
27. Ganz PA, Rowland J, Meyerowitz BE, Desmond K. Impact of different adjuvant strategies on quality of life (QOL) in breast cancer survivors (BCS). Eur J Cancer 1998; 34 (Suppl 1): Abstract S39.
28. Tørisen HM. Felleskatalog 1997/98, 39th edition, Felleskatalogen AS Oslo, 1997.
29. The tariff of public out-patient treatment valid from July 1st 1997. Oslo: The National Health Administration, 1997.
30. Løber J, Søgaard J, Mouridsen HT, Jørgensen J. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. Acta Oncol 1988; 27: 767-71.
31. Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients. First results of intergroup trial int 0102. American Society of Clinical Oncology (ASCO), 34th Annual Meeting, Los Angeles, CA, 1998; 17: Abstract 2.
32. Galligioni E, Cetto G, Nascimben O, et al. High dose epirubicin and cyclophosphamide (EC) vs. cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial. Eur J Cancer 1998; 34 (Suppl. 1): Abstract P84.
33. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol 1997; 8: 65-70.
34. Koopmanschap MA, Rutten FFH, van Inevald BM. Reply to Johannesson's and Karlsson's comment. J Health Econ 1997; 6: 253-9.
35. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labour and health status in economic evaluation of health care. Int J Technol Assess Health Care 1996; 12: 405-15.
36. Koopmanschap MA, Vanlnevald BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005-10.
37. Liljas B. How to calculate indirect costs in economic evaluations. PharmacoEcon 1998; 13: 1-7.
38. Office of Technology Assessment, US Congress. Cost and effectiveness of colorectal cancer screening in the elderly. Background paper. Washington DC: US Government Printing Office, 1990.
39. Fletcher RH. Screening for colorectal cancer. Weighing the alternatives. In: Perry MC, Whippen D, eds. American Society of Clinical Oncology Educational Book, 33rd Annual Meeting, Alexandria, VA: Am Soc Clin Oncol 1997; 200-4.
40. Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP) or CMFP plus tamoxiphen compared to CMF for postmenopausal breast cancer patients. Cancer 1990; 65: 200-6.
41. Norum J. Should the municipality pay for hospital patients waiting for transferral to nursing homes? J Nor Med Assoc 1999; 119: 1434-6.
42. Troms County Council, Department of Health. Taxes for health institutions in Troms county valid from January 1st 1998. Troms County Council February 20th 1998.
43. National Health Administration. A proposal for payment by the local authorities for patients staying in hospital waiting for transferral to nursing homes. Oslo: National Health Administration, 1998.
44. Koopmanschap MA, van Ineveld BM, Miltenburg TE. Costs of home care for advanced breast and cervical cancer in relation to cost-effectiveness of screening. Soc Sci Med 1992; 35: 979-85.
45. Abdyldaev RA, Abdyldaev TA. Cost of adjuvant chemotherapy (CT) with CMF and tamoxophen in breast cancer (BC). Eur J Cancer 1998; 34 (Suppl 1): Abstract P2.